3Read Jr CH,Tansey M J,Menda Y.A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patient[J].J Clin Endocrinol Metab,2004-89(9):4229-4233.
4Chiovato L Fiore E,Vitti P,et al.Outcome of Thyroid Function in Groves' Patients Treated with Radioiodine:Role of Thyroid-Stimulating and Thyrotropin-Blocking Antibodies and of Radioiodine-Induced Thyroid Damage[J].J Clin Endocrinol Metab,1998,83(1):40-46.
5Mizutori Y, Chen CR, MeLachlan SM, et al. The thyrotrepin receptor hinge region is not simply a scaffold for the Leueine - Rich Domain but contributes to ligand binding and signal transduction. Molecular Endocrinology. 2008,22(5) :1171.
6Kohn LD, Harii N. Thyrotropin receptor autoantibodies (TSHRAbs) : epitopes, origins and clinical significance. Autoimmunity. 2003,36(6 -7) :331.
7Morgenthaler NG, Ho SC, Minich WB. Stimulating and blocking TSH - receptor autoantibodies from patients with Graves's disease and antoimmune hypothyroidsm have very similar concentration, TSH - receptor affinity and binding sites. J Clin Endocrinol Metab. 2007,92(3 ) :1058.
8Costagliola S, Morgenthaler NG, Hoermann R, et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves's disease. J Clin Endocrinol Metab. 1999,84(1) :90.
9Villata D, Orunesu E, Tozzoli R, et al. Analytical and diagnostic accuracy of "second generation" assays for thyrotropin receptor antibodies with radioactive and chemiluminescent tracers. J Clin Pathol. 2004,57 (4) :378.
10Pedersen IB, Knudsen N, Perrild H, et al. TSH - receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goiter: a comparison of two competitive binding assays. Clin Endocrinol. 2001,55(3) :381.
